DYNE THERAPEUTICS INC (DYN) Forecast, Price Target & Analyst Ratings
NASDAQ:DYN • US26818M1080
14.6 USD
-1.55 (-9.6%)
At close: Mar 3, 2026
14.57 USD
-0.03 (-0.21%)
After Hours: 3/3/2026, 8:06:32 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for DYNE THERAPEUTICS INC (DYN).
Forecast Snapshot
Consensus Price Target
$41.48
+ 184.11% Upside
Next Earnings Forecast
Release DateMay 6, 2026
PeriodQ1 / 2026
EPS Estimate-$0.81
Revenue Estimate
ChartMill Buy Consensus
84.00%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$41.48
Upside
+ 184.11%
From current price of $14.60 to mean target of $41.48, Based on 20 analyst forecasts
Low
$23.23
Median
$40.80
High
$63.00
Price Target Revisions
1 Month
3.77%
3 Months
13.89%
Price Target Summary
20 analysts have analysed DYN and the average price target is 41.48 USD. This implies a price increase of 184.11% is expected in the next year compared to the current price of 14.6.
The average price target has been revised upward by 13.89% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
84.00%
DYN was analyzed by 20 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about DYN.
In the previous month the buy percentage consensus was at a similar level.
DYN was analyzed by 20 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-03 | Chardan Capital | Maintains | Buy -> Buy |
| 2026-03-03 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2026-03-03 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-20 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-12-15 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-12-11 | Stifel | Maintains | Buy -> Buy |
| 2025-12-10 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2025-12-09 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-12-09 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-12-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-14 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-11-12 | Oppenheimer | Maintains | Perform -> Perform |
| 2025-11-06 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-11-06 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-10 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2025-08-25 | Raymond James | Upgrade | Outperform -> Strong Buy |
| 2025-08-06 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-07-31 | Stifel | Maintains | Buy -> Buy |
| 2025-07-29 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-07-29 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-07-29 | Raymond James | Reiterate | Outperform -> Outperform |
| 2025-07-15 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-06-26 | Jones Trading | Initiate | Buy |
| 2025-06-18 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-06-18 | Baird | Maintains | Outperform -> Outperform |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 6, 2026
PeriodQ1 / 2026
EPS Estimate-$0.81
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q22.81%
Number of Analysts9
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.28%
EPS (3 Months)
2.71%
Next Earnings Summary
DYN is expected to report earnings on 5/6/2026. The consensus EPS estimate for the next earnings is -0.81 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A 405.87% | N/A 165.57% | N/A 78.48% | N/A 26.23% | N/A 21.89% | N/A 12.78% | ||||||||
| EBITDA YoY % growth | -4.78M | -13.56M -183.68% | -57.95M -327.36% | -148.94M -157.01% | -169.28M -13.66% | -240.489M -42.07% | -342.213M -42.30% | N/A -31.40% | N/A -20.42% | N/A -8.22% | N/A 20.14% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -4.8M | -13.83M -188.13% | -58.65M -324.08% | -150.03M -155.81% | -170.96M -13.95% | -242.162M -41.65% | -343.886M -42.01% | N/A -36.52% | N/A -9.15% | N/A 0.94% | N/A 31.14% | N/A 116.94% | N/A 964.66% | N/A 34.34% | N/A 32.21% | N/A 15.36% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -2.91 -15.59% | -3.24 -11.34% | -3.94 -21.60% | -3.35 14.97% | -3.54 -5.67% | N/A 6.88% | N/A 7.71% | N/A 34.00% | N/A 126.16% | N/A 459.62% | N/A 63.00% | N/A 33.94% | N/A 14.90% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.81 22.81% | -0.84 13.32% | -0.86 -12.79% | -0.86 -13.29% |
| Revenue Q2Q % growth | ||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -125.273M -2.37% | -127.85M -10.41% | -133.078M -16.85% | -135.54M -13.82% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
12.74%
EPS Next 5 Year
23.13%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-18.59%
EBIT Next 5 Year
-7.43%
DYNE THERAPEUTICS INC / DYN Forecast FAQ
What do analysts expect the price target to be for DYNE THERAPEUTICS INC (DYN)?
20 analysts have analysed DYN and the average price target is 41.48 USD. This implies a price increase of 184.11% is expected in the next year compared to the current price of 14.6.
Can you provide the upcoming earnings date for DYNE THERAPEUTICS INC?
DYNE THERAPEUTICS INC (DYN) will report earnings on 2026-05-06.
What are the consensus estimates for DYN stock next earnings?
The consensus EPS estimate for the next earnings of DYNE THERAPEUTICS INC (DYN) is -0.81 USD and the consensus revenue estimate is 0 USD.